Clicky

Spectrum Pharmaceuticals, Inc.(SPPI)

Description: Spectrum Pharmaceuticals, Inc., a biotechnology company, engages in acquiring, developing, and commercializing prescription drug products primarily in the areas of hematology and oncology. The company's oncology products include FUSILEV for patients with osteosarcoma after high-dose methotrexate therapy, and to diminish toxicity and counteract the effects of impaired methotrexate elimination or inadvertent overdose of folic acid antagonists; FOLOTYN, a folate analogue metabolic inhibitor for the treatment of patients with relapsed or refractory peripheral T-cell lymphoma; and ZEVALIN, a prescribed form of cancer therapy which combines a source of radiation with an antibody. It also develops apaziquone that is under Phase III clinical trial for non-muscle invasive bladder cancer; and belinostat, which is under Phase II registrational trial for the various hematological and solid tumors. In addition, the company develops ozarelix that is under randomized phase II clinical trial in prostate cancer patients; ortataxel, which has completed Phase II studies in solid tumor patients; lucanthone, an orally administered small-molecule that has completed preclinical tests; SPI-1620, which has completed Phase I study is a peptide agonist of endothelin B receptors; RenaZorb, a second-generation lanthanum-based nanoparticle phosphate binding agent; and SPI-2012, a drug for the treatment of chemotherapy induced neutropenia. It has strategic collaborations with Allergan, Inc., Nippon Kayaku Co. Ltd., and Handok Pharmaceuticals Co. Ltd. for the development and commercialization of apaziquone; and TopoTarget A/S for the development and commercialization of belinostat. The company was formerly known as NeoTherapeutics, Inc. and changed its name to Spectrum Pharmaceuticals, Inc. in December 2002. Spectrum Pharmaceuticals, Inc. was founded in 1987 and is based in Henderson, Nevada.


Keywords: Medicine Biotechnology Cancer Solid Tumors Radiation Acid Chemotherapy Prostate Cancer Lymphoma Phosphates Hematology Prescription Drugs Bladder Cancer Sarcoma Drug Products Treating Cancer Cancer Therapy Neutropenia Oncology Products Methotrexate Osteosarcoma Prescription Drug Products Spectrum Pharmaceuticals Non Muscle Invasive Bladder Cancer Ozarelix Prescription Drug Product

Home Page: www.sppirx.com

SPPI Technical Analysis

Pilot House – Lewis Wharf
Boston, MA 02110
United States
Phone: 617 586 3900


Officers

Name Title
Mr. Thomas J. Riga Pres, CEO & Director
Ms. Nora E. Brennan Exec. VP & Chief Financial Officer
Mr. Keith M. McGahan J.D., L.L.M. Exec. VP, Chief Legal Officer & Corp. Sec.
Dr. Francois J. Lebel FRCPC, M.D. Exec. VP & Chief Medical Officer
Mr. Bimal R. Shah VP of Corp. & Bus. Devel.
Mr. Michael A. Grabow Exec. VP & Chief Bus. Officer
Dr. Lyndah K. Dreiling M.B.A., M.D. Sr. VP of Clinical Devel.

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 4.7483
Trailing PE: 0
Price-to-Book MRQ: 2.3953
Price-to-Sales TTM: 0
IPO Date: 1996-09-26
Fiscal Year End: December
Full Time Employees: 163
Back to stocks